1. Home
  2. SEM vs AUPH Comparison

SEM vs AUPH Comparison

Compare SEM & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Select Medical Holdings Corporation

SEM

Select Medical Holdings Corporation

HOLD

Current Price

$14.94

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$15.94

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEM
AUPH
Founded
1996
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.6B
IPO Year
2009
1999

Fundamental Metrics

Financial Performance
Metric
SEM
AUPH
Price
$14.94
$15.94
Analyst Decision
Buy
Buy
Analyst Count
3
4
Target Price
$16.33
$17.25
AVG Volume (30 Days)
1.0M
1.2M
Earning Date
02-19-2026
11-04-2025
Dividend Yield
1.67%
N/A
EPS Growth
N/A
N/A
EPS
0.87
0.55
Revenue
$5,368,760,000.00
$265,808,000.00
Revenue This Year
$5.53
$21.76
Revenue Next Year
$4.33
$16.45
P/E Ratio
$19.68
$28.76
Revenue Growth
45.29
20.62
52 Week Low
$11.65
$6.55
52 Week High
$20.83
$16.54

Technical Indicators

Market Signals
Indicator
SEM
AUPH
Relative Strength Index (RSI) 54.32 55.71
Support Level $14.73 $15.64
Resistance Level $15.18 $16.54
Average True Range (ATR) 0.30 0.38
MACD -0.08 -0.08
Stochastic Oscillator 20.64 57.55

Price Performance

Historical Comparison
SEM
AUPH

About SEM Select Medical Holdings Corporation

Select Medical Holdings Corp is a healthcare company that operates through three segments: critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics. Critical illness recovery hospitals which derives maximum revenue consists of hospitals designed to serve the needs of patients recovering from critical illnesses, often with complex medical needs. The rehabilitation hospital segment consists of hospitals designed to serve patients that require intensive physical rehabilitation care. Patients are typically admitted to critical illness recovery hospitals and rehabilitation hospitals from general acute care hospitals. The outpatient rehabilitation segment consists of clinics that provide physical, occupational, and speech rehabilitation services.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: